After a year, Dong-E-E-Jiao has重订 its incentive plan, with significant adjustments to the stocks grant price and restriction release threshold | Quick announcement summary.

① After a year, Dong-E-E-Jiao has revised its incentive plan, increasing the grant price of the initially granted restricted Stocks from 24.98 yuan per share to 37.22 yuan per share. ② There have also been significant adjustments to the performance assessment requirements at the company level, with the revised net asset return assessment absolute value being higher than before the revision.

cls.cnJan 10 10:49 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Warned for issues such as inaccurate disclosure of executive compensation, the latest response from the management of Ant Financial College. | Speed reading announcement

①Today, the management of Jiaoda Angli held a media communication meeting to respond to the issues mentioned in the warning letter from the Shanghai Securities Regulatory Bureau received yesterday. ②Regarding the inaccurate disclosure of executive compensation, Jiaoda Angli stated that the specific situation involves the former management of the company purchasing group insurance and receiving refunds to individual accounts. ③The company has filed a lawsuit against the then executives and related personnel, with the case involving a value of 21.0393 million yuan.

cls.cnDec 4, 2024 09:15 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27, 2024 09:29 ET

Tj Darentang USD: Wang Lei succeeds Zhang Mingrui as chairman, the company's development global strategy "will not change" | Express announcement

① Zhang Mingrui has applied to resign from the positions of tj darentang usd chairman, director, and chairman of the Global Strategy Committee due to work-related reasons. ② Wang Lei, the general manager of the company, will take over as chairman, with company officials stating that the enterprise's development strategy "will not change".

cls.cnNov 26, 2024 08:20 ET

tj darentang usd: Planning to sell 13% of the shares of Zhongmei SmithKline, still awaiting approval from the antitrust review | Direct hit on the shareholders' meeting

① Today's tj darentang shareholder meeting approved the proposal to sell a 13% stake in Sino-US Tianjin Schering Pharmaceutical Co., Ltd. (referred to as: Sino-US Schering). The company's chairman, Zhang Mingrui, stated: "Sino-US Schering is an outstanding company, and this stake sale is mainly due to the expiration of the 40-year cooperation period." ② The sale of the stake still requires approval from He Liyang after anti-monopoly review by the State Administration for Market Regulation.

cls.cnNov 22, 2024 06:16 ET